MetaCap

Disc Medicine (IRON) vs Parabilis Medicines (PBLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Parabilis Medicines is the larger company by market cap ($3.44 billion vs $3.42 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRON+11.73%PBLS-13.16%
+35%+2%-31%
Jun 10, 20261 yearNov 20, 2026
IRON+10.52%PBLS+0.66%
+57%+18%-20%
Jun 8, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRON versus PBLS key metrics
MetricIRONPBLS
Share price$75.14$27.44
Market cap$3.42B$3.44B
1-day change-1.27%-0.67%
YTD return-5.38%—
1-year return-18.86%—
5-year return-14.22%—
EPS (TTM)$-6.34$-3.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-212.18M—
52-week high$99.50$42.49
52-week low$40.00$22.66
Distance from 52-week high-24.48%-35.42%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+69.94%+49.42%
Average volume951.56K975.55K
Shares outstanding45.54M123.68M
Employees173145
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Disc Medicine

IRON stock →

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees

About Parabilis Medicines

PBLS stock →

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

IRON vs PBLS FAQ

Which is bigger, Disc Medicine or Parabilis Medicines?

Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.44B compared with $3.42B for Disc Medicine (IRON).

Are Disc Medicine and Parabilis Medicines in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons